Robert Zerbib

3.0k total citations
26 papers, 722 citations indexed

About

Robert Zerbib is a scholar working on Oncology, Immunology and Hematology. According to data from OpenAlex, Robert Zerbib has authored 26 papers receiving a total of 722 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Oncology, 12 papers in Immunology and 10 papers in Hematology. Recurrent topics in Robert Zerbib's work include Immune Cell Function and Interaction (11 papers), Multiple Myeloma Research and Treatments (7 papers) and Cancer Immunotherapy and Biomarkers (7 papers). Robert Zerbib is often cited by papers focused on Immune Cell Function and Interaction (11 papers), Multiple Myeloma Research and Treatments (7 papers) and Cancer Immunotherapy and Biomarkers (7 papers). Robert Zerbib collaborates with scholars based in France, United States and Netherlands. Robert Zerbib's co-authors include Pascale André, Éric Vivier, H Laborit, Sjoerd H. van der Burg, Émilie Narni-Mancinelli, Amir Horowitz, Thorbald van Hall, Dan Fu Ruan, Michael A. Caligiuri and Don M. Benson and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Robert Zerbib

24 papers receiving 711 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Robert Zerbib France	12	481	480	137	115	37	26	722
Amal Rayan Egypt	13	135 0.3×	108 0.2×	30 0.2×	142 1.2×	23 0.6×	34	413
Gianluca Zaccarello Italy	8	217 0.5×	240 0.5×	100 0.7×	189 1.6×	16 0.4×	11	683
Nadine Voelxen Germany	8	310 0.6×	61 0.1×	33 0.2×	103 0.9×	53 1.4×	11	534
Sanmay Bandyopadhyay United States	12	168 0.3×	87 0.2×	73 0.5×	147 1.3×	20 0.5×	16	450
J. Hesselgesser United States	5	428 0.9×	342 0.7×	76 0.6×	143 1.2×	23 0.6×	6	734
Jens Gertow Sweden	14	175 0.4×	166 0.3×	202 1.5×	61 0.5×	11 0.3×	29	525
Chloë Marden United Kingdom	10	228 0.5×	144 0.3×	44 0.3×	123 1.1×	5 0.1×	13	444
Dan Davini United States	8	554 1.2×	99 0.2×	28 0.2×	100 0.9×	8 0.2×	13	748
Jeremy Wechsler United States	9	324 0.7×	124 0.3×	85 0.6×	250 2.2×	17 0.5×	11	787
Ernesto López Chile	9	283 0.6×	164 0.3×	31 0.2×	114 1.0×	17 0.5×	13	486

Countries citing papers authored by Robert Zerbib

Since Specialization

Citations

This map shows the geographic impact of Robert Zerbib's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert Zerbib with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert Zerbib more than expected).

Fields of papers citing papers by Robert Zerbib

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert Zerbib. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert Zerbib. The network helps show where Robert Zerbib may publish in the future.

Co-authorship network of co-authors of Robert Zerbib

This figure shows the co-authorship network connecting the top 25 collaborators of Robert Zerbib. A scholar is included among the top collaborators of Robert Zerbib based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert Zerbib. Robert Zerbib is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Chemaly, Roy F., Alexander P. J. Vlaar, Endry H. T. Lim, et al.. (2025). 85. Improved Survival with Dual Immunomodulator Treatment of ARDS by blocking C5a and IL-6 Activity: Subanalysis from the PANAMO Study in Critically Ill COVID-19 Patients. Open Forum Infectious Diseases. 12(Supplement_1).

Lim, Endry H. T., Bruce Burnett, Robert Zerbib, et al.. (2024). VILOBELIMAB IN COMBINATION WITH TOCILIZUMAB MAY SYNERGISTICALLY IMPROVE MORTALITY IN CRITICALLY ILL COVID-19 PATIENTS: A POST-HOC ANALYSIS OF THE PHASE III PANAMO STUDY. CHEST Journal. 166(4). A2225–A2226. 1 indexed citations

Shorr, Andrew F., Alexander P. J. Vlaar, Endry H. T. Lim, et al.. (2024). Vilobelimab in Combination With Tocilizumab or Baricitinib Dramatically Improves Mortality in Critically Ill COVID-19 Patients: A Subgroup Analysis. A5511–A5511.

Demaria, Olivier, Julien Carvelli, Joanna Fares, et al.. (2020). 483 Association of COVID-19 inflammation with activation of the C5a-C5aR1 axis. SHILAP Revista de lepidopterología. A299.1–A299. 11 indexed citations

Hall, Thorbald van, Pascale André, Amir Horowitz, et al.. (2019). Monalizumab: inhibiting the novel immune checkpoint NKG2A. Journal for ImmunoTherapy of Cancer. 7(1). 263–263. 202 indexed citations

Massard, Christophe, Philippe A. Cassier, Johanna C. Bendell, et al.. (2019). Preliminary results of STELLAR-001, a dose escalation phase I study of the anti-C5aR, IPH5401, in combination with durvalumab in advanced solid tumours. Annals of Oncology. 30. v492–v492. 14 indexed citations

Cohen, Romain, G. Lefebvre, Marshall R. Posner, et al.. (2019). Monalizumab in combination with cetuximab in patients (pts) with recurrent or metastatic (R/M) head and neck cancer (SCCHN) previously treated or not with PD-(L)1 inhibitors (IO): 1-year survival data. Annals of Oncology. 30. v460–v460. 16 indexed citations

Vey, Norbert, Lionel Karlin, Florence Broussais, et al.. (2018). A phase 1 study of lirilumab (antibody against killer immunoglobulin-like receptor antibody KIR2D; IPH2102) in patients with solid tumors and hematologic malignancies. Oncotarget. 9(25). 17675–17688. 110 indexed citations

Cohen, Roger B., Jérôme Fayette, Marshall R. Posner, et al.. (2018). Abstract CT158: Phase II study of monalizumab, a first-in-class NKG2A monoclonal antibody, in combination with cetuximab in previously treated recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): Preliminary assessment of safety and efficacy. Cancer Research. 78(13_Supplement). CT158–CT158. 10 indexed citations

10.

Cohen, Roger B., Sébastien Salas, Caroline Even, et al.. (2017). Abstract 5666: Safety of the first-in-class anti-NKG2A monoclonal antibody monalizumab in combination with cetuximab: a phase Ib/II study in recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN). Cancer Research. 77(13_Supplement). 5666–5666. 2 indexed citations

11.

Benson, Don M., Adam D. Cohen, Sundar Jagannath, et al.. (2015). A Phase I Trial of the Anti-KIR Antibody IPH2101 and Lenalidomide in Patients with Relapsed/Refractory Multiple Myeloma. Clinical Cancer Research. 21(18). 4055–4061. 147 indexed citations

12.

Vey, Norbert, Anthony Gonçalvès, Lionel Karlin, et al.. (2015). A phase 1 dose-escalation study of IPH2102 (lirilumab, BMS-986015, LIRI), a fully human anti KIR monoclonal antibody (mAb) in patients (pts) with various hematologic (HEM) or solid malignancies (SOL).. Journal of Clinical Oncology. 33(15_suppl). 3065–3065. 15 indexed citations

13.

Benson, Don M., Adam D. Cohen, Craig C. Hofmeister, et al.. (2013). A Phase I Trial Of Anti-KIR Monoclonal Antibody IPH2101 and Lenalidomide For Multiple Myeloma. Blood. 122(21). 3181–3181. 3 indexed citations

14.

Decaux, Olivier, Alain Renault, Véronique Sebille, et al.. (2012). Predictive Factors of Survival After Thalidomide Therapy in Advanced Multiple Myeloma: Long-Term Follow-Up of a Prospective Multicenter Nonrandomized Phase II Study in 120 Patients. Clinical Lymphoma Myeloma & Leukemia. 12(6). 418–422. 2 indexed citations

15.

Benson, Don M., Adam D. Cohen, Nikhil C. Munshi, et al.. (2012). A Phase I Trial of the Anti-Inhibitory KIR Antibody, IPH2101, and Lenalidomide in Multiple Myeloma: Interim Results. Blood. 120(21). 4058–4058. 2 indexed citations

16.

Kropff, Martin, Jens Hillengaß, Tadeusz Robak, et al.. (2011). Thalidomide versus dexamethasone for the treatment of relapsed and/or refractory multiple myeloma: results from OPTIMUM, a randomized trial. Haematologica. 97(5). 784–791. 43 indexed citations

17.

Yakoub‐Agha, Ibrahim, Chantal Doyen, Cyrille Hulin, et al.. (2006). A multicenter prospective randomized study testing non-inferiority of thalidomide 100 mg/day as compared with 400 mg/day in patients with refractory/relapsed multiple myeloma: Results of the final analysis of the IFM 01–02 study. Journal of Clinical Oncology. 24(18_suppl). 7520–7520. 28 indexed citations

18.

Zerbib, Robert, et al.. (1993). Anxiolytic activity of melatonin in mice: involvement of benzodiazepine receptors.. PubMed. 82(2). 131–42. 38 indexed citations

19.

Zerbib, Robert & H Laborit. (1990). Chronic stress and memory: Implication of the central cholinergic system. Pharmacology Biochemistry and Behavior. 36(4). 897–900. 14 indexed citations

20.

Laborit, H & Robert Zerbib. (1987). Role of various second messengers in the memorization of a passive or active avoidance. 12(4). 193–204. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact